Last update 14 Dec 2024

Streptomycin Sulfate

Last update 14 Dec 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2,4-diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside, Streptomycin, Streptomycin sulfate (JP17/USP)

+ [2]

Target

30S subunit

Mechanism

30S subunit inhibitors(30S ribosomal subunit inhibitors)

Therapeutic Areas

Infectious DiseasesEye DiseasesOther Diseases

Active Indication

Ocular inflammationTuberculosis

Inactive Indication-

Originator Organization

Leshan Sanjiu Long March Pharmaceuticals Co. Ltd.

Active Organization

Wuhan Jiuan Medicine Industry Co. Ltd.

Leshan Longmarch Medicine Industry Co., Ltd.

Leshan Sanjiu Long March Pharmaceuticals Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 1981),

Ocular inflammation

Regulation-

Structure

Molecular FormulaC42H84N14O36S3

InChIKeyQTENRWWVYAAPBI-YCRXJPFRSA-N

CAS Registry3810-74-0

Clinical Trials associated with Streptomycin Sulfate

IRCT20160523028008N4 / CompletedPhase 3IIT

Comparative study of response to treatment and recurrence of brucellosis in the 4 and 6 week treatment groups with doxycycline, streptomycin and hydroxychloroquine. A single blinded randomised clinical trial.

Start Date20 Feb 2019

Sponsor / Collaborator

Hamedan University of Medical Sciences

NCT02128308 / CompletedPhase 1IIT

A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic Characteristics of Second-Line Anti-Tuberculosis Agents After Multiple Oral/Intramuscular Administration in Healthy Male Volunteers

This study aims to investigate the pharmacokinetic characteristics of second-line anti-tuberculosis agents after oral/intramuscular administration in healthy male volunteers.

Start Date01 Nov 2013

Sponsor / Collaborator

Seoul National University Hospital

NCT02604849 / CompletedNot ApplicableIIT

Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin

The identification of all cases (44 patients) was carried out from the database of microbiology, University Hospital Reina Sofía and the University Hospital of Jerez. For the identification of controls, in case of neutropenic patients, all colonized patients that were included during the study period did not receive any decolonitation treatment; in case of non-neutropenic patients it was studied a paired control by the presence of risk factors that indicated the beginning of decolonitation treatment.

Start Date01 Jul 2012

Sponsor / Collaborator

Maimonides Institute for Biomedical Research of Cordoba

100 Clinical Results associated with Streptomycin Sulfate

100 Translational Medicine associated with Streptomycin Sulfate

100 Patents (Medical) associated with Streptomycin Sulfate

23,939

Literatures (Medical) associated with Streptomycin Sulfate

01 Mar 2025·Infectious disorders drug targets

A Comparison of Antibiotics’ Resistance Patterns of E. coli and B. subtilis in their Biofilms and Planktonic Forms

Article

Author: Sharma, Shagun ; Bist, Renu ; Mathur, Shubhita ; Jhalora, Vandana

Background::

A biofilm refers to a community of microbial cells that adhere to surfaces that are surrounded by an extracellular polymeric substance. Bacteria employ various defence mechanisms, including biofilm formation, to enhance their survival and resistance against antibiotics.

Objective::

The current study aims to investigate the resistance patterns of Escherichia coli (E. coli) and Bacillus subtilis (B. subtilis) in both biofilms and their planktonic forms

Methods::

E. coli and B. subtilis were used to compare resistance patterns in biofilms versus planktonic forms of bacteria. An antibiotic disc diffusion test was performed to check the resistance pattern of biofilm and planktonic bacteria against different antibiotics such as penicillin G, streptomycin, and ampicillin. Biofilm formation and its validation were done by using quantitative (microtiter plate assay) and qualitative analysis (Congo red agar media).

Results::

A study of surface-association curves of E. coli and B. subtilis revealed that surface adhesion in biofilms was continuously constant as compared to their planktonic forms, thereby confirming the increased survival of bacteria in biofilms. Also, biofilms have shown high resistance towards the penicillin G, ampicillin and streptomycin as compared to their planktonic form.

Conclusion::

It is safely inferred that E. coli and B. subtilis, in their biofilms, become increasingly resistant to penicillin G, ampicillin and streptomycin

01 Mar 2025·BIOSENSORS & BIOELECTRONICS

Phase engineered amorphous-crystalline MIL-101(CuFe)@AuNPs with enhanced photothermal activity for sensitive immunochromatographic bimodal detection of streptomycin

Article

Author: Liu, Sijie ; Wang, Jianlong ; Zhuo, Junchen ; Yin, Xuechi ; Shan, Jinrui ; Shi, Longhua ; Sun, Jing ; Cheng, Jie ; Zhang, Daohong ; Gong, Weijie ; Wang, Shaochi

Phase engineering-assisted tuning of the plasma resonance properties of multifunctional nanocomposites provides an excellent opportunity to improve analytical performance. It is anticipated to break the dominating bottleneck of insufficient signal brightness in identifying imperceptible variation of the target concentration and further enhance the sensitive immunochromatographic assays (ICAs) analysis. Herein, by simply assembling isolated gold nanoparticles (AuNPs) on the surface of MIL-101(CuFe) (named MCF) with a tunable size and crystal phase, we synthesized amorphous-crystalline MCF@AuNPs nanocomposites as immuno signal tracers. For the first time, we utilized phase transformation to assist in realizing the effective regulation of the plasma resonance properties of MCF@AuNPs. It exhibits extraordinary colorimetric intensity, photothermal conversion efficiency (59.1%), stability, and dispersion, all of which facilitate the construction of sensitive and accurate bimodal complementary ICA. With a proof-of-concept for streptomycin, the MCF@AuNPs-ICA showed the limit of detection (LOD) at 0.14 ng mL^-1 with remarkable university in different samples. This work demonstrates the importance of the rational design of phase-transformation-assisted tuning plasma resonance properties to improve analytical performance with terrific potential for point-of-care (POC) diagnostic applications.

01 Feb 2025·FOOD CHEMISTRY

Multi-residue analysis of four aminoglycoside antibiotic pesticides in plant agricultural products

Article

Author: Deng, Sirui ; Liu, Dan ; Deng, Qianqian ; Li, Shuhui

Simplified and effective pretreatment methods combined with high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) for the determination of four aminoglycoside antibiotic pesticides kasugamycin, validamycin, streptomycin sulfate and zhongshengmycin in high starchy content matrix (rice), high water and high acidic content matrix (citrus) and high water content matrix (melon) were established. Single-factor and central composite design (CCD) experiments were employed to optimize the pretreatment conditions, resulting in the optimal factor combinations and achieving scientifically accurate outcomes. Validation results proved satisfactory, with all four target compounds exhibiting correlation coefficients (r) exceeding 0.99 within the linear range in three matrices. The recoveries were 81.5-102.2 %, and both inter-day and intra-day relative standard deviations (RSDs) were below 10.7 %. The limits of detection (LODs) were 0.1-4.0 μg/kg, with limits of quantitation (LOQs) consistently at 50 μg/kg. Furthermore, the methods were applied to potato, grape, and cucumber matrices to further validate their applicability.

News (Medical) associated with Streptomycin Sulfate

10 Dec 2024

·www.globenewswire.com

Microbix Assisting EMQN with Novel Genetic-Test EQA Program

For Rapid Identification of Patients Susceptible to Antibiotic-Induced Hearing LossMISSISSAUGA, Ontario and MANCHESTER, United Kingdom, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the go-live of a program to support the accurate identification of patients who carry a gene-variant associated with increased susceptibility to hearing loss following treatment with a widely-used class of antibiotics. This first-of-its kind EQA program is intended to help ensure the proficiency of Point-of-Care Testing (“POCT”) and acute-care labs that are assessing whether patients carry the MT-RNR1 m.1555A>G gene variant. It is estimated that one in 500 persons carry this variant that can lead to profound and irreversible hearing loss upon exposure to aminoglycoside antibiotics. This class of antibiotics include Gentamycin, Kanamycin, Streptomycin, and Tobramycin, which are used to treat a wide range of “gram negative” bacterial infections. Of particular concern are newborn babies who are suspected to be at risk of bacterial sepsis – a life-threatening condition that can lead to death from multi-organ failure if not treated promptly with appropriate antibiotic drugs and other acute medical care. Microbix-produced quality assessment products (“QAPs™”), formatted onto Copan® FLOQSwabs®, are being used in this EMQN EQA program to help assess the proficiency and accuracy of such acute care genetic testing. The QAPs provide samples that participants can process like cheek or buccal swabs, enabling them to verify the accuracy of MT-RNR1 assays in their POCT. With a subscription to this EMQN program, participants will receive three samples every two months (18 per year), helping them to ensure the accuracy of their testing on an ongoing basis and thereby make the most reliable diagnoses possible. Sean Sales, Operations Director at EMQN, commented, “It has been a pleasure to have Microbix’s assistance in making the QAPs for this groundbreaking and important new EQA program. Acute care physicians need the information to be able to evaluate the risk-benefit of antibiotic treatments and no patient should have to face a lifetime of hearing loss when tests to identify this risk are available.” Cameron Groome, CEO and President at Microbix also commented, “We’re pleased to help enable the creation of EQA for this clinically-important decision-making. Our expertise was joined to that of EMQN and Copan to ensure that accurate testing and properly-directed treatment is available for patients worldwide. This QAP marks Microbix’s entry into supporting the accuracy of genetic tests, adding to our established presence in infectious diseases and emerging role in oncology.” UK and international labs can enroll in this EQA program (code POCT MT-RNR1 25) via EMQN CIC at https://www.emqn.org/our-eqa-schemes/ and enquiries about Microbix QAPs can be directed to customer.service@microbix.com. About EMQN CICEMQN is a Manchester, UK based company that provides quality assurance tools and specialized knowledge to the human genomic testing community through External Quality Assessment (EQA) schemes. Its work helps guarantee the best possible molecular diagnostic procedure, analytical performance, and clinical interpretation. EMQN’s highly qualified peer group of assessors take pride in their thought leadership position and are committed to regularly publishing best practice guidelines and other information for the molecular diagnostics field. EMQN is accredited by the United Kingdom Accreditation Service (UKAS) to the international standard for EQA scheme providers, ISO 17043. About Microbix Biosystems Inc.Microbix Biosystems Inc. creates proprietary biological products for human health, with over 100 skilled employees and sales now targeting C$ 2.0 million or more per month. It makes and exports a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR compliant CE marked products across the EU. Forward-Looking InformationThis news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of the tests, the EQA program, EMQN, Copan, or their relevance, Microbix’s products or services, business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its presentations, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity or timeliness of delivery), currency exchange rates, maintaining adequate working capital or raising new capital on acceptable terms or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. Microbix cautions that all forward-looking information is inherently uncertain, and actual performance may be affected by a number of material factors, some of which are beyond its control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent Microbix’s judgement as of the date of this new release, and it is under no obligation to update or alter any forward-looking information. Please visit https://microbix.com or www.sedar.com for recent Microbix news and filings. For further information, please contact Microbix at: Cameron Groome, CEO(905) 361-8910Jim Currie, CFO(905) 361-8910Deborah Honig, Investor RelationsAdelaide Capital Markets(647) 203-8793 ir@microbix.com Copyright © 2024 Microbix Biosystems Inc. Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix Biosystems Inc.Copan®, FLOQ®, and FLOQSwab® are trademarks of Copan Italia S.p.A.

17 Apr 2024

·www.sciencedaily.com

New class of antimicrobials discovered in soil bacteria

Researchers have discovered toxic protein particles, shaped like umbrellas, that soil bacteria known as Streptomyces secrete to squelch competitors in their crowded microbial communities, especially others of their own species. What makes these newly detected antibacterial toxins different is that, unlike the Streptomyces' small-molecule antibiotics, umbrella toxins are large complexes composed of multiple proteins. They are also far more specific in the bacteria they target. They tend to go after bacteria that form branching filaments, an usual growth pattern among bacteria. The scientists are intrigued by the potential clinical clinical applications of this discovery, because they suspect the pathogens that cause tuberculosis and diphtheria might be sensitive to umbrella toxins. Researchers have discovered toxic protein particles, shaped like umbrellas, that soil bacteria known as Streptomyces secrete to squelch competitors, especially others of their own species. The discovery of the umbrella toxin particles and related information about their structures, composition and mode of action were published April 17 in Nature. The umbrella toxin proteins are the latest example of these bacteria's varied, combative strikes on their microscopic rivals. The crowded, diverse bacteria communities in which they live are a melee of antimicrobial attacks, counterattacks and defenses. Ironically, many clinically used antibiotics are derived directly from, or are inspired by, molecules that bacteria use against each other in their natural habitat. Streptomyces' chemical weaponry against their competitors is one of the richest sources of such molecules. Among them is the common, broad-spectrum drug streptomycin. What makes these newly detected antibacterial toxins different is that, unlike the Streptomyces' small-molecule antibiotics, umbrella toxins are large complexes composed of multiple proteins. They are also far more specific in the bacteria they target. The authors of the Nature paper speculate that these properties of umbrella toxins explain why they escaped discovery for more than 100 years of research on toxins produced by Streptomyces. Genes encoding umbrella toxins were originally uncovered through a bioinformatics search for new bacterial toxins. In biochemical and genetic experiments led by Qinqin Zhao in Joseph Mougous' microbiology lab at the University of Washington School of Medicine, the scientists learned that these toxins associate with other proteins in a large complex. Cryo-electron microscopy of these protein complexes was performed by Young Park in the laboratory of David Veesler, professor of biochemistry at the UW School of Medicine and an investigator of the Howard Hughes Medical Institute. These studies revealed that the toxin complexes Qinqin isolated adopt a striking appearance befitting their discovery in Seattle. They look like umbrellas. "The shape of these particles is quite peculiar, and it will be interesting in future work to learn how their unusual morphology helps them eliminate target bacteria," noted Mougous, a professor of microbiology at the UW School of Medicine and a Howard Hughes Medical Institute investigator. The scientists then sought to determine the targets of these toxins by screening their effects on every organism they could conceivably target, from fungi to 140 different bacteria, including some taken from sorghum plants in the lab of study author Devin Coleman at the University of California-Berkeley and the U.S. Department of Agriculture Agricultural Research Service. . Among these potential adversaries, the toxins specifically targeted their own brethren: other Streptomyces species. "We think this exquisite specificity may be due to the proteins that make up the spokes of the umbrella, which vary across the particles. These include proteins that might latch onto specific sugars found on the surface of competitor bacteria," commented study author S. Brook Peterson, a senior scientist in the Mougous lab. By analyzing the thousands of publicly available bacterial genomes, study authors Dapeng Zhang of St. Louis University and his graduate student Youngjun Tan found that many other species of bacteria also have the genes to manufacture umbrella particle toxins. Interestingly, these species all form branching filaments, an unusual mode of growth among bacteria. In addition to the many questions remaining to be answered about the basic biology of umbrella toxin particles, Mougous and his colleagues are intrigued by their potential clinical applications. They suspect that the bacteria that cause tuberculosis and diphtheria may be sensitive to umbrella toxins. They note these same bacteria have become resistant to traditional antibiotics. Umbrella toxin particles might be worth exploring, the scientists suggested, for their potential to subdue these serious disease-causing bacteria.

30 Jan 2024

·www.prnewswire.com

Sound Pharma to present positive interim data from its Phase 2b Cystic Fibrosis STOP Ototoxicity Trial

SEATTLE, Jan. 30, 2024 /PRNewswire/ -- Sound Pharmaceuticals (SPI) will present the Phase 2b STOP Ototoxicity data that was selected for podium presentation at the Association for Research in Otolaryngology (ARO) Midwinter Meeting in Anaheim, CA (February 3-7). This initial safety and efficacy study of SPI-1005 (ebselen) to prevent and treat aminoglycoside-induced ototoxicity enrolled 60 adult CF patients undergoing intravenous (IV) tobramycin for the treatment of acute pulmonary exacerbation. Ototoxicity (hearing loss, tinnitus, vertigo or dizziness) is a common side effect of aminoglycoside antibiotics (tobramycin, amikacin, gentamycin and streptomycin). Currently, there are no FDA approved therapies for the prevention/treatment of aminoglycoside ototoxicity or the treatment of any other type of sensorineural hearing loss, tinnitus, or dizziness. In the Phase 1b observational study (N=20), SPI reported that a 14-day course of IV tobramycin resulted in ototoxicity rates of 89% and 93%, at 2 and 4-weeks after aminoglycoside treatment was completed (Harruff, Journal of Cystic Fibrosis, 2021). In the Phase 2b interventional study, adult patients were randomized in a double blinded fashion to 3 different doses of ebselen or placebo, taken orally for 21 days within 3 days of starting IV tobramycin. In the Phase 2b study (N=40), the ototoxicity rates were 73% and 63%, at 2 and 4-weeks after aminoglycoside treatment was completed, a statistically significant reduction when compared to the Phase 1b study (p-value <0.05). No significant differences in age, duration of IV tobramycin, concomitant medications, respiratory status, or baseline hearing loss were observed between the studies. Interim analysis of the Phase 2b results shows a dose proportional decrease in the ototoxicity rate (from placebo, 200, 400, to 600 mg ebselen), with the 400 and 600 mg dose having ototoxicity rates of 44% and 43% at 4-weeks (400 mg, p-value <0.05). "To our knowledge, these are the first positive results of an ototoxicity intervention trial in humans undergoing antibiotic treatment for pulmonary exacerbation," said Jonathan Kil, MD, SPI's Co-Founder and CEO. Results from two other preclinical studies involving ebselen treatment, a novel anti-inflammatory compound that has also shown positive results in clinical trials involving acute noise exposure, bipolar mania, and Meniere's disease, will be presented at the ARO. The CFF provided a $2.2M Therapeutic Development Award to SPI to support the studies. Details of this trial (NCT02819856) can be viewed online at , or by visiting . SOURCE Sound Pharmaceuticals

Clinical ResultPhase 2

100 Deals associated with Streptomycin Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
D01350	Streptomycin Sulfate	J01GA01 A07AA04	DB01082

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ocular inflammation	CN	Leshan Longmarch Medicine Industry Co., Ltd.	01 Jan 1981
Ocular inflammation	CN	Wuhan Jiuan Medicine Industry Co. Ltd.	01 Jan 1981
Ocular inflammation	CN	Leshan Sanjiu Long March Pharmaceuticals Co. Ltd.	01 Jan 1981
Tuberculosis	US	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ATS2022	Not Applicable	Mycobacterium Avium-Intracellulare Infection	-	Streptomycin	chyhojfjyd(ajlyneelxo) = 1 patient kjxjfjjtuj (qsjqxvvkqj ) View more	-	15 May 2022
AAAAI2012	Not Applicable	T-Lymphocytopenia	-	Streptomycin treatment	nflidchshb(qgjqchkuru) = wfoutlskqh emqufxguwa (huziqqjwtd )	-	01 Feb 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis